AstraZeneca bought the rights to Spanish group Almirall’s lung drugs for $2.1 billion. AstraZeneca rejected a $118 billion takeover offer from Pfizer in May. The British drug maker said it would pay an initial $875 million and up to $1.22 billion if the drugs reached sales and development targets. Pascal Soriot, AstraZeneca’s CEO, is determined to build a strong independent future for the firm. AstraZeneca now has the right to develop and commercialize Almirall’s lung drugs including Eklira or aclidinium, plus all the experimental therapies the company is working on.